gdc-0973 and Systemic-Inflammatory-Response-Syndrome

gdc-0973 has been researched along with Systemic-Inflammatory-Response-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for gdc-0973 and Systemic-Inflammatory-Response-Syndrome

ArticleYear
Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 07-01, Volume: 28, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Female; Humans; Indoles; Melanoma; Middle Aged; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib

2017